Document is current
Any future updates will be listed below
-
Authors
Bright, Uri https://orcid.org/0009-0000-9102-7804
Beck, Sarah
Galimberti, Marco https://orcid.org/0000-0001-6052-156X
Gupta, Priya
Chen, Yu https://orcid.org/0000-0002-4768-9269
Dao, Cecilia
Nunez, Yaira Z.
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Zhou, Yu
Zhang, Yingzhe
Choi, Karmel W.
Levey, Daniel F.
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
-
Funding
Funding for this research was provided by:
U.S. Department of Veterans Affairs (I01CX001849, 575B, IK2BX005058)
U.S. Department of Health & Human Services | National Institutes of Health (R01DA058862, R01DA054869)
- License Information
-
More Information
Article History
Received: 21 May 2025
Revised: 18 September 2025
Accepted: 22 September 2025
First Online: 3 October 2025
Competing interests
: HRK is a member of advisory boards for Altimmune and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals and Altimmune; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Imbrium, Indivior, Kinnov, Lilly, Otsuka, and Pear; and an inventor on U.S. provisional patent 63/710,270 “Multi-ancestry Genome-wide Association Meta-analysis of Buprenorphine Treatment Response,” filed 29 October. JG is paid for editorial work by the journal Complex Psychiatry. All other authors report no conflicts.
